Drug DiscoveryResearch & Development June 12, 2023 EdgeCap Partners buys majority stake in Comac Medical By PBR Staff Writer Comac founder and CEO Dr Milen Vrabevski and its other shareholders will retain a significant minority stake. The companies have not disclosed the financial terms of the deal.
Women's Health June 9, 2023 Cosette acquires worldwide rights to Endoceutics’ Intraros prescription drug By PBR Staff Writer The transaction includes 108 issued and pending patents globally with the latest expiring this year including three Orange Book listed patents. The acquisition will expedite Cosette’s women’s health
Drug Manufacturing June 8, 2023 Samsung Biologics, Pfizer partner for biosimilars portfolio manufacturing By PBR Staff Writer Initially, the companies signed a manufacturing agreement in March last year for a Pfizer product. As per the new agreement terms, Samsung Biologics will provide Pfizer with more
Oncology June 7, 2023 Janssen seeks US FDA approval of new indication for Carvykti By PBR Staff Writer Carvykti is intended to treat adults with relapsed or refractory multiple myeloma who have previously received a minimum of one line of therapy including a proteasome inhibitor, an
Inflammation June 6, 2023 Rani, Celltrion expand partnership for development of adalimumab biosimilar By PBR Staff Writer Under a new license and supply agreement, Celltrion will supply adalimumab biosimilar drug substance CT-P17 that is required for RT-105. Rani has an exclusive license to use the
Gastric Cancer June 5, 2023 NMPA grants BTD to Innovent’s olverembatinib to treat SDH-deficient GIST By PBR Staff Writer The designation was granted based on the results from an ongoing Phase Ib/II study of olverembatinib carried out in China. The study demonstrated a clinical benefit rate of
Osteoarthritis June 2, 2023 Levolta partners with Tabuk for OA therapy commercialisation in MEA region By PBR Staff Writer Tabuk is a fully owned subsidiary of Astra Industrial Group. Under the agreement, Tabuk will hold the marketing authorisation and will be responsible for registering, importing, and commercialising
Approvals June 1, 2023 EMA grants PRIME designation to Rocket’s AAV-based gene therapy By PBR Staff Writer The designation for the investigational gene therapy was granted based on positive safety and efficacy data from the Phase I study in patients with Danon Disease. A favourable
Cell Therapy May 31, 2023 eXmoor pharma raises $35m to boost cell and gene therapy production By PBR Staff Writer The fundraise saw the participation of new and existing investors Kineticos Ventures and MVM Partners, respectively. Kineticos Ventures president and CEO Frank Lis is joining eXmoor board as
DermatologyOsteoarthritis May 30, 2023 Abiogen Pharma acquires 97.09% stake in EffRx Pharmaceuticals By PBR Staff Writer Abiogen Pharma’s business spans across many integrated aspects: research and development, manufacturing of pharmaceuticals under its own brand or third-party contracts, and marketing of its own and licensed